Innovation Showcases
Human induced pluripotent stem cells (iPSCs) offer transformative potential for disease modeling and regenerative medicine, but current genome engineering tools lack the scale, speed, and precision required for clinical applications. Our proprietary platform, Geno-Writing™, overcomes these limitations by enabling:
(1) bi-allelic and precise modification of endogenous loci up to 100 kb, and
(2) stable integration and expression of up to 12 transgenes in human iPSCs within two months.
This capability for rapid, large-scale genomic rewriting sets a new benchmark in iPSC engineering. As a proof of concept, we are developing iPSC-based therapies for Type 1 Diabetes, addressing two key challenges:
(1) Immune tolerance — Geno-Writing™ allows selective deletion of HLA genes at the native locus, avoiding the functional drawbacks and immune risks of conventional methods like B2M or CIITA disruption.
(2) β cell differentiation — Using our proprietary gene prioritization algorithm, we identified and precisely knocked out key regulators, significantly improving β cell yield and insulin secretion from iPSCs.
These results demonstrate Geno-Writing™ as a robust and versatile platform for creating next-generation, allogeneic iPSC-derived cell therapies.